Novartis AG ADR (NVSN)

1,608.64
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    1,608.64 - 1,608.64
Trading near 52-week Low

Novartis ADR has hit the lowest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

NVSN Historical Data

Time Frame:
Daily
09/14/2021 - 10/04/2022
1,608.641,608.641,608.641,608.640.45K-7.49%
1,608.641,608.641,608.641,608.640.45K-7.49%
1,738.821,690.001,738.821,690.002.25K-1.59%
1,767.001,767.001,767.001,767.000.01K+1.92%
1,733.681,733.681,733.681,733.686.19K+5.76%
1,639.261,639.261,639.261,639.262.39K-1.61%
1,666.001,666.001,666.001,666.000.02K-2.00%
1,700.001,700.001,700.001,700.000.05K-6.86%
1,825.171,788.011,825.171,788.014.55K+2.14%
1,787.001,787.001,787.001,787.000.30K+1.25%
1,765.001,765.001,765.001,765.000.03K-0.56%
1,775.001,775.001,775.001,775.000.03K0.00%
1,775.001,775.001,775.001,775.000.03K0.00%
1,775.001,779.191,779.191,775.000.03K+0.85%
1,760.001,760.001,760.001,760.007.31K-1.07%
1,779.001,733.631,779.001,733.630.02K-1.96%
1,814.571,814.571,814.571,814.570.02K+0.81%
1,800.001,800.001,800.001,800.000.02K+1.21%
1,778.551,778.551,778.551,778.550.02K+5.73%
1,682.131,685.001,685.001,682.130.07K-1.04%
1,699.781,699.781,699.781,699.780.04K+0.58%
1,690.001,690.001,690.001,690.000.03K+2.05%
1,656.001,656.001,656.001,656.000.01K-0.10%
1,657.711,706.001,706.001,657.710.02K-2.67%
1,703.201,703.201,703.201,703.200.50K-0.30%
1,708.351,708.351,708.351,708.3512.60K+2.34%
1,669.251,669.251,669.251,669.250.03K-0.50%
1,677.641,677.641,677.641,677.640.12K+0.34%
1,672.001,682.001,682.001,672.000.65K-1.99%
1,706.001,706.001,706.001,706.000.02K+6.05%
Highest: 1,825.17Lowest: 1,608.64Difference: 216.53Average: 1,720.61Change %: -7.49
  • NVS reported solid results for Q1 that included a 10% jump in sales for its top-selling Cosentyx psoriatic arthritis drug. With a diverse portfolio of pharmaceuticals and strong momentum in a down market, NVS is worth a look for many reasons
    1
    • Thanks in part to strong performance, this is one of a few stocks that has posted positive gains in 2022 despite headwinds elsewhere in the market.
      0
      • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
        1
        • buy
          0
          • A
            0
            • just to know. I'm lost.this is the company that bought the medicines company?
              0
              • before investing in @novartis, read #teampia (twitter).
                0
                • sell 89 expecting 80 timeframe 5 days
                  1
                  • Long ENDOCYTE... I work in the field
                    0
                    • $NVS: Novartis AG Looking at All Options Including IPO for Alcon Unit.. This is HUGE catalyst for $NVS share holders!!!!!
                      0